Loss-Making Noile-Immune Biotech Inc. (TSE:4893) Expected To Breakeven In The Medium-Term

With the business potentially at an important milestone, we thought we'd take a closer look at Noile-Immune Biotech Inc.'s (TSE:4893) future prospects. Noile-Immune Biotech Inc. researches and develops CAR-T cells for novel cancer immunotherapies. The JP¥6.0b market-cap company’s loss lessened since it announced a JP¥793m loss in the full financial year, compared to the latest trailing-twelve-month loss of JP¥706m, as it approaches breakeven. Many investors are wondering about the rate at which Noile-Immune Biotech will turn a profit, with the big question being “when will the company breakeven?” We've put together a brief outline of industry analyst expectations for the company, its year of breakeven and its implied growth rate.

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.

Noile-Immune Biotech is bordering on breakeven, according to some Japanese Biotechs analysts. They expect the company to post a final loss in 2027, before turning a profit of JP¥1.4b in 2028. Therefore, the company is expected to breakeven roughly 2 years from today. In order to meet this breakeven date, we calculated the rate at which the company must grow year-on-year. It turns out an average annual growth rate of -6.4% is expected,

We're not going to go through company-specific developments for Noile-Immune Biotech given that this is a high-level summary, but, take into account that typically a biotech has lumpy cash flows which are contingent on the product type and stage of development the company is in. So, periods of lower growth in the upcoming years is not out of the ordinary, particularly when a company is in a period of investment.

See our latest analysis for Noile-Immune Biotech

Before we wrap up, there’s one aspect worth mentioning. Noile-Immune Biotech currently has no debt on its balance sheet, which is quite unusual for a cash-burning biotech, which typically has high debt relative to its equity. The company currently operates purely off its shareholder funding and has no debt obligation, reducing concerns around repayments and making it a less risky investment.

Next Steps:

There are too many aspects of Noile-Immune Biotech to cover in one brief article, but the key fundamentals for the company can all be found in one place – Noile-Immune Biotech's company page on Simply Wall St. We've also put together a list of key aspects you should further examine:

1. Historical Track Record: What has Noile-Immune Biotech's performance been like over the past? Go into more detail in the past track record analysis and take a look at the free visual representations of our analysis for more clarity.
2. Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on Noile-Immune Biotech's board and the CEO’s background.
3. Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.